Teva- Pharmaceutical Industries Ltd. ADR (NYSE:TEVA)’s traded shares stood at 8.96 million during the last session, with the company’s beta value hitting 1.07. At the close of trading, the stock’s price was $12.78, to imply a decrease of -3.03% or -$0.4 in intraday trading. The TEVA share’s 52-week high remains $14.47, putting it -13.22% down since that peak but still an impressive 44.52% since price per share fell to its 52-week low of $7.09. The company has a valuation of $14.33B, with an average of 10.43 million shares over the past 3 months.
Teva- Pharmaceutical Industries Ltd. ADR (NYSE:TEVA) trade information
After registering a -3.03% downside in the last session, Teva- Pharmaceutical Industries Ltd. ADR (TEVA) has traded red over the past five days. The stock hit a weekly high of 13.70, dropping -3.03% in its intraday price action. The 5-day price performance for the stock is -7.86%, and -4.27% over 30 days. With these gigs, the year-to-date price performance is 22.41%.
Teva- Pharmaceutical Industries Ltd. ADR (TEVA) estimates and forecasts
Looking at statistics comparing Teva- Pharmaceutical Industries Ltd. ADR share performance against respective industry, we note that the company has underperformed competitors. Teva- Pharmaceutical Industries Ltd. ADR (TEVA) shares are 47.58% up over the last 6 months, with its year-to-date growth rate lower than industry average at -7.42% against 21.70%. Revenue is forecast to grow 30.00% this quarter before jumping 3.60% for the next one. The rating firms project that company’s revenue will grow 0.10% compared to the previous financial year.
Revenue forecast for the current quarter as set by 7 analysts is $3.73 billion. Meanwhile, for the quarter ending Jun 2024, a total of 7 analyst(s) estimate revenue growth to $4 billion.Earnings reports from the last fiscal year show that sales brought in $3.63 billion and -$ respectively in the corresponding quarters.
An assessment of the company’s 5-year growth patterns shows that annual earnings grew an estimated 26.63% for the past 5-year period. While 2024 is set for a -6.18% return in earnings, projections for the next 5 years are at 1.60% annually.
TEVA Dividends
Teva- Pharmaceutical Industries Ltd. ADR has its next earnings report out in May. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. Teva- Pharmaceutical Industries Ltd. ADR has a forward dividend ratio of 0, with the share yield ticking at 0.00% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 0.00%.
